Cytokeratin 8 & 18 (B22.1 & B23.1) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology
Detection of cytokeratins 8 and 18 by immunohistochemistry (IHC) with Cytokeratin 8 & 18 (B22.1 & B23.1) Mouse Monoclonal Antibody may be used to aid in the diagnosis of adenocarcinomas.
Cytokeratin (CK) 8 and 18 are both members of the cytokeratin family, a family of intermediate filament proteins that are produced by epithelial cells. Cytokeratin 8 and 18 are both low molecular weight cytokeratins that are produced by simple epithelium, which lines the ducts and glands of many tissues including breast, gastrointestinal tract, pancreas, and prostate.1,2 Both CK 8 and CK 18 are expressed in most adenocarcinomas.1-5 Immunohistochemistry for cytokeratin 8 & 18 shows a cytoplasmic pattern of staining.
In combination with other antibodies, this product may be used as an aid in diagnosis.
- Moll, R et al. "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells." Cell vol. 31,1 (1982): 11-24.
- Menz, Anne et al. "Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors." Molecular medicine (Cambridge, Mass.) vol. 27,1 16. 15 Feb. 2021,
- Shao, Mu-Min et al. "Keratin expression in breast cancers." Virchows Archiv : an international journal of pathology vol. 461,3 (2012): 313-22.
- Choi, Hong-Jo et al. "Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma." Annals of surgical oncology vol. 9,1 (2002): 13-9.
- Sasaki, M et al. "Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: a comparison with genetic analysis of K-ras." Histopathology vol. 32,3 (1998): 199-208.
- Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983;14:767
- Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am CMC81829090 EN Rev. 9.0 p. 8 J Clin Pathol. 1980 May; 73(5):626-32. doi: 10.1093/ajcp/73.5.626. PMID: 6155065.
Specifications
- Reactivity: paraffin
- Control: Prostate (Cytoplasmic); Pancreas (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 9.0 (CMC81829090)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 818M-90 |
| 0.1 mL concentrate | 818M-94 |
| 0.5 mL concentrate | 818M-95 |
| 1.0 mL concentrate | 818M-96 |
| 1.0 mL predilute ready-to-use | 818M-97 |
| 7.0 mL predilute ready-to-use | 818M-98 |
For in vitro diagnostic (IVD) use in Canada
| 25.0 mL predilute ready-to-use | 818M-90 |
| 0.1 mL concentrate | 818M-94 |
| 0.5 mL concentrate | 818M-95 |
| 1.0 mL concentrate | 818M-96 |
| 1.0 mL predilute ready-to-use | 818M-97 |
| 7.0 mL predilute ready-to-use | 818M-98 |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 818M-90 |
| 0.1 mL concentrate | 818M-94 |
| 0.5 mL concentrate | 818M-95 |
| 1.0 mL concentrate | 818M-96 |
| 1.0 mL predilute ready-to-use | 818M-97 |
| 7.0 mL predilute ready-to-use | 818M-98 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 818M-90-RUO |
| 0.1 mL concentrate (RUO) | 818M-94-RUO |
| 0.5 mL concentrate (RUO) | 818M-95-RUO |
| 1.0 mL concentrate (RUO) | 818M-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 818M-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 818M-98-RUO |
To request information on this product in additional countries, please click the button below.
